David Spigel, MD, discusses the significant benefits of durvalumab as consolidation therapy following standard ...

DelveInsight's "TIBSOVO Market Size, Forecast, and Market Insight Report" highlights the details around TIBSOVO, the first ...

Patients with solid tumor malignancies had better survival after ICI therapy if they were obese than if they had a normal BMI.

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been approved by the European ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organization ...

AstraZeneca‘s IMFINZI® (durvalumab) has gained FDA approval for use in adult patients with muscle-invasive bladder cancer ...

Market capitalisation stands at Rs 19,771.25 crore. The share touched a 52-week high of Rs 9,049.95 and a 52-week low of Rs 5 ...

EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...

The European Commission has approved a new regimen from AstraZeneca, which combines the company’s durvalumab with ...

Matt Galsky, MD, discusses the phase 3 NIAGARA trial that led to the recent FDA approval of durvalumab in muscle-invasive ...

欧盟委员会的决定基于AEGEAN III期临床试验结果，该试验显示与单独使用新辅助化疗相比，疾病复发、进展或死亡风险降低了32%。试验结果已发表在《新英格兰医学杂志》上。这一进展进一步巩固了阿斯利康的强劲表现，该公司报告在过去十二个月内收入同比增长18%，达到541亿美元。

UK pharma major AstraZeneca (LSE: AZN) today reported extended approvals in Europe for two of its cancer drugs: Imfinzi ...